Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AZD6489 in Adults 60 Years of Age and Older
NCT07717840Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD6489 in respiratory syncytial virus infection (RSV) (4 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of immediate unsolicited adverse events at 30 minutes, Incidence of injection site and systemic solicited adverse reactions and 5 more. Started Jul 2026; status: active, not recruiting.
02
Drugs
AZD6489
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07717840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07717840.